drugset / Trial / NCT06148311

Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia

NCT06148311

Phase 2 Enrolling by invitation 15 enrolled NYU Langone Health Food and Drug Administration (FDA) · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this placebo controlled interventional study is to collect preliminary data on administering dexmedetomidine in patients with Familial Dysautonomia (FD) during a rapid cessation of autonomic crisis. The primary aims are to assess the feasibility and evaluate if measurements of heart rate, blood pressure and oxygen saturation can predict the start of an autonomic crisis. Funding Source- FDA OOPD

Timeline

Start
2024-07-01
Primary completion
2027-01-01
Completion
2027-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 120 ug Other

Indications